chlorine dioxide
Small moleculeexperimental
Chlorine dioxide is a chemical compound with the formula ClO2 that exists as yellowish-green gas above 11 °C, a reddish-brown liquid between 11 °C and −59 °C, and as bright orange crystals below −59 °C. It is usually handled as an aqueous solution. It is commonly used as a bleach. More recent developments have extended its applications in food processing and as a disinfectant. — Wikipedia
Clinical trial activity
12 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
4
Earliest trial started Aug 1, 2004 (NCT01341041)
Timeline
Indications
Approved for
Studied for
- Chlorhexidine · Phase 4
- Coronavirus Infections · Phase 2
- COVID-19 · Phase 2
- Frail Elderly · Phase 4
- Halitosis · Phase 4
- Mucositis · Phase 4
- Nursing Homes · Phase 4
- Oral Hygiene · Phase 4
- Pharyngeal Diseases · Phase 2
- SARS-CoV-2 · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Virus Diseases · Phase 2
- Wounds and Injuries · Early Phase 1
Mechanism of action
- Unspecified targetOTHER
other
Chemistry & pharmacology
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaChlorine dioxide ↗
- ChEMBLCHEMBL4297725 ↗
Also known as
- alcide
- aseptrol
- chlorine dioxide
- chlorine dioxide
- chlorine dioxide
- chlorine dioxide
- chlorine dioxide, 17o-labeled
- chlorine dioxide, 35cl,1-(18)o-labeled
- chlorine dioxide, 35cl-labeled
- chlorine dioxide, 37cl,1-(18)o-labeled
- chlorine dioxide, 37cl-labeled
- chlorine dioxide, monohydrate
- chlorine oxide (clo2)
- dioxiclear
- microclear
- rennew-d
- tristel
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07265102 | N/A | Sep 5, 2023 | Can Tho University of Medicine and Pharmacy, Ho Chi Minh City University of Medicine and Pharmacy |
| NCT04621149 | Phase 2 | Nov 15, 2020 | Profact, Inc. |
| NCT04409873 | Phase 2 | Jul 1, 2020 | University of California, San Francisco |
| NCT03602066 | Phase 2 | Oct 1, 2018 | National Cancer Institute (NCI), University of Arizona |
| NCT04838054 | Phase 4 | Mar 15, 2018 | Rowpar Pharmaceuticals, Inc., Stony Brook University |
| NCT03533335 | Phase 4 | Jun 1, 2014 | The University of Hong Kong |
| NCT02689297 | Phase 4 | Sep 30, 2013 | Tokyo Medical and Dental University |
| NCT02113137 | Phase 4 | Sep 1, 2013 | Tokyo Medical and Dental University |
| NCT00867035 | N/A | Mar 1, 2008 | University of California, San Francisco |
| NCT00748943 | Phase 1 | Mar 31, 2007 | Tokyo Medical and Dental University |
| NCT00655772 | Phase 1 | Feb 28, 2007 | Tokyo Medical and Dental University |
| NCT01341041 | Early Phase 1 (Phase 1) | Aug 1, 2004 | Rhode Island Hospital |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tokyo Medical and Dental University | Academic/Hospital | 4 | 4 | 2 | 2007 |
| University of California, San Francisco | Academic/Hospital | 2 | 2 | 2 | 2008 |
| Can Tho University of Medicine and Pharmacy | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Ho Chi Minh City University of Medicine and Pharmacy | Academic/Hospital | 1 | 0 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2018 |
| Profact, Inc. | For profit | 1 | 1 | 1 | 2020 |
| Rhode Island Hospital | Academic/Hospital | 1 | 1 | 1 | 2004 |
| Rowpar Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2018 |
| Stony Brook University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| The University of Hong Kong | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Arizona | Academic/Hospital | 1 | 1 | 1 | 2018 |
11 organizations
Page 1 / 1